Black Diamond Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary
06/11/2024 05:17
* Black Diamond Therapeutics Inc BDTX.OQ reported a
quarterly
adjusted loss of 28 cents per share for the quarter ended
September 30, higher than the same quarter last year, when the
company reported EPS of -45 cents. The mean expectation of
seven analysts for the quarter was for a loss of 37 cents per
share. Wall Street expected results to range from -41 cents
to -33 cents per share.
* Reported revenue was zero; analysts expected zero.
* Black Diamond Therapeutics Inc's reported EPS for the
quarter
was a loss of 28 cents.
* The company reported a quarterly loss of $15.56 million.
* Black Diamond Therapeutics Inc shares had fallen by 25.3%
this
quarter and gained 15.7% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 7.8%
in the last three months.
* In the last 30 days, two analysts negatively revised
earnings
estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Black Diamond
Therapeutics Inc is $15.50
This summary was machine generated from LSEG data November 6 at
05:17 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.37 -0.28 Beat
Jun. 30 2024 -0.39 -0.36 Beat
Mar. 31 2024 -0.43 -0.35 Beat
Dec. 31 2023 -0.47 -0.34 Beat